Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027

Mark T. Reding, Ingrid Pabinger, Shadan Lalezari, Elena Santagostino, Maria Elisa Mancuso

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)e201-e204
JournalHaemophilia
Volume26
Issue number4
DOIs
StatePublished - Jul 1 2020

Bibliographical note

Funding Information:
Dr Inga Bayh of Bayer AG, Wuppertal, Germany, was responsible for the statistical analysis of this study. This study was supported by Bayer. Medical writing assistance was provided by Fishawack Communications Ltd., which was fully funded by Bayer.

Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.

Keywords

  • BAY 94-9027
  • PROTECT VIII trial
  • bleeding
  • damoctocog alfa pegol
  • haemophilia A
  • target joint

PubMed: MeSH publication types

  • Letter

Cite this